1/3/2007

Maryland's biotech companies made significant progress last year in their march to market commercial products, analysts say. More companies turned the corner "in terms of receiving significant money and the realization of new drugs coming to market," said Bob Eaton, president of MdBio Foundation.

Related Summaries